Teva Pharmaceutical Industries Limited (NYSE:TEVA) had its price objective decreased by Sanford C. Bernstein from $28.00 to $20.00 in a research note issued to investors on Thursday, Marketbeat reports. Sanford C. Bernstein currently has a market perform rating on the stock.

A number of other brokerages also recently weighed in on TEVA. Vetr downgraded Teva Pharmaceutical Industries Limited from a hold rating to a sell rating and set a $32.27 target price on the stock. in a report on Tuesday, July 4th. BidaskClub raised Teva Pharmaceutical Industries Limited from a hold rating to a buy rating in a report on Wednesday, July 5th. Wells Fargo & Company reaffirmed a hold rating on shares of Teva Pharmaceutical Industries Limited in a report on Tuesday, June 27th. Jefferies Group LLC reaffirmed a hold rating and issued a $33.00 target price on shares of Teva Pharmaceutical Industries Limited in a report on Friday, June 23rd. Finally, Cantor Fitzgerald set a $31.00 target price on Teva Pharmaceutical Industries Limited and gave the company a hold rating in a report on Thursday, June 22nd. Five analysts have rated the stock with a sell rating, nineteen have given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of Hold and an average target price of $30.91.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at 17.19 on Thursday. The company’s 50 day moving average price is $18.13 and its 200 day moving average price is $28.20. The company’s market cap is $17.47 billion. Teva Pharmaceutical Industries Limited has a 52-week low of $15.22 and a 52-week high of $51.51.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.06 by ($0.07). The company had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The company’s quarterly revenue was up 12.9% compared to the same quarter last year. During the same period in the prior year, the company earned $1.25 EPS. Equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/25/teva-pharmaceutical-industries-limited-teva-price-target-cut-to-20-00.html.

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th were issued a dividend of $0.085 per share. The ex-dividend date of this dividend was Friday, August 25th. This represents a $0.34 dividend on an annualized basis and a yield of 1.98%. Teva Pharmaceutical Industries Limited’s payout ratio is -15.36%.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Capital Research Global Investors grew its position in shares of Teva Pharmaceutical Industries Limited by 13.8% during the 2nd quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock valued at $2,535,518,000 after purchasing an additional 9,260,426 shares in the last quarter. Franklin Resources Inc. grew its position in shares of Teva Pharmaceutical Industries Limited by 11.1% during the 2nd quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock valued at $2,218,958,000 after purchasing an additional 6,685,844 shares in the last quarter. FMR LLC grew its position in shares of Teva Pharmaceutical Industries Limited by 16.7% during the 2nd quarter. FMR LLC now owns 42,844,979 shares of the company’s stock valued at $1,423,310,000 after purchasing an additional 6,115,853 shares in the last quarter. Northern Cross LLC grew its position in shares of Teva Pharmaceutical Industries Limited by 14.0% during the 2nd quarter. Northern Cross LLC now owns 17,795,579 shares of the company’s stock valued at $591,169,000 after purchasing an additional 2,184,172 shares in the last quarter. Finally, Nordea Investment Management AB grew its position in shares of Teva Pharmaceutical Industries Limited by 2.5% during the 2nd quarter. Nordea Investment Management AB now owns 12,884,810 shares of the company’s stock valued at $428,033,000 after purchasing an additional 311,894 shares in the last quarter. Hedge funds and other institutional investors own 56.76% of the company’s stock.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.